

# Biotechnological Inventions

**Revised Edition** 


Moral Restraints and Patent Law

**OLIVER MILLS** 

# Biotechnological Inventions

## Moral Restraints and Patent Law Revised Edition

# OLIVER MILLS National University of Ireland, Galway



#### © Oliver Mills 2010

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise without the prior permission of the publisher.

Oliver Mills has asserted his right under the Copyright, Designs and Patents Act, 1988, to be identified as the author of this work.

Published by

Ashgate Publishing Limited

Wey Court East Union Road Farnham Surrey, GU9 7PT

England

Ashgate Publishing Company

Suite 420 101 Cherry Street Burlington VT 05401-4405

USA

www.ashgate.com

#### **British Library Cataloguing in Publication Data**

Mills, Oliver.

Biotechnological inventions: moral restraints and patent

law. -- 2nd ed.

1. Biotechnology--Patents. 2. Patent laws and legislation--Europe. 3. Patent laws and legislation--United States. 4. Biotechnology industries--Law and

legislation--Europe. 5. Biotechnology industries--Law and

legislation--United States.

I. Title

346'.0486-dc22

#### Library of Congress Cataloging-in-Publication Data

Mills, Oliver.

Biotechnological inventions: moral restraints and patent law / by Oliver Mills.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-7546-7774-1 (hardback) -- ISBN 978-0-7546-9524-0 (ebook)

1. Biotechnology--Patents. 2. Patent laws and legislation--Europe. 3. Patent

laws and legislation--United States. 4. Biotechnology industries--Law and legislation--Europe. 5. Biotechnology industries--Law and legislation--United States. I. Title.

K1519.B54M55 2010

346.04'86--dc22

2010005660

ISBN 9780754677741 (hbk) ISBN 9780754695240 (ebk)



Printed and bound in Great Britain by MPG Books Group, UK

#### Table of Cases

In the Matter for an Application for A and H [1927] 44 RPC 298.

Ex parte Allen 2 USPQ 1425 [1987].

Anaesthetic Supplies Pty Ltd Rescare Ltd [1993/1994] Federal Court of Australia.

Re Arzerberger 46 USPQ 32 [1940].

Asahi Kasei Kogyo (KK's) Application [1991] RPC 485.

Bedford v Hunt 3 F Cas 37 Circuit Court Massachusetts [1817].

Re Bergy, Coats and Malik 195 USPQ 344 [1977].

Biogen Inc. v Medeva PLC [1997] RPC 1.

Biogen/Hepatitis B [1995] EPOR 1.

Ex parte Blythe 1885 Commission Decision 1862, 86 (Commission Patent 1885).

Brenner v Manson 148 USPQ 696 [1966].

Catnic Components v Hill and Smith [1982] RPC 183.

Chiron Corp. and others v Organon Teknika Ltd and others [1994] FSR 202.

Ciba-Geigy/Propagating Material [1979/85] EPOR vol. C 758.

Ciba-Geigy/Synergistic herbicides [1987] EPOR vol. 5 302.

Collaborative/Preprorennin [1990] EPOR 361.

Commercial Solvents Corporation v Synthetic Products Co. Ltd [1926] 43 RPC 185.

Ex parte Deuel, Thomas F 27 USPQ 1360 [1993].

Diamond, Commissioner of Patents and Trademarks v Chakrabarty 206 USPQ 193 [1980].

EFAMOL/Pharmaceutical Compositions [1987] EPOR vol. 4 229.

Eli Lily and Co v Human Genome Sciences, Inc. [2008] RPC 29.

Exxon / Fuel Oils [1994] EPOR 149.

Funk Brothers Seed Company v Kalo Inoculant Company 76 USPQ 280 [1948].

Genentech 1/Polypeptide Expression [1989] 1 EPOR 1.

Genentech's Inc.'s Patent [1989] RPC 147.

General Tire and Rubber Co. v The Firestone Tyre and Rubber Co. Ltd and others [1972] RPC 457.

Re Graeme I Bell 26 USPQ 2d 1529 [1993].

Graham v John Deere Co. of Kansas City 148 USPQ 459 [1966].

Harvard/Onco-Mouse Examining Division [1989] OJ EPO 451, Board of Appeal [1990] EPOR 501, Examining Division [1991] EPOR 525.

H. Lundbeck A/S v Generics (UK) Ltd [2008] RPC 19.

Ex parte Hibberd 227 USPQ 443 [1985].

Hotchkiss v Greenwood [1805] 11 How 248.

Howard Florey/Relaxin [1995] EPOR 541.

Improver Corporation v Remington Consumer Products Ltd. [1989] RPC 69.

Juicy Whip Inc. v Orange Bang Inc. and Unique Beverage Dispensers Inc. 185 F 3d 1364 [1999] (decision of 6 Aug 1999).

Kewanee Oil Company v Bicron Corporation et al. 181 USPQ 673 [1974].

Koppe v Burnstingle 29 F 2d 923 (DRI 1929).

Ex parte Latimer [1889] Commission Decision 13 Dec 1889.

Lowell v Lewis 15 F Cas 1018 Circuit Court Massachusetts [1817]

Lubrizol/hybrid plants [1990] EPOR 173.

Masterman's Design [1991] RPC 89.

May & Baker v Boots Pure Drug Co. Ltd [1950] 67 RPC 23.

In re Merat and Cochez 186 USPQ 471[1975].

Merrell Dow v Norton [1996] RPC 76

Mobil/Friction reducing additive [1990] EPOR 73.

Molnlycke AB and another v Procter & Gamble and others [1994] RPC 49.

Ex parte Moore 115 USPQ 145 [1957]

Re Murphy 200 USPQ 801 [1977].

National Automatic Devise Co. v Lloyd 40 F 89 (ND Illinois 1889).

Netherlands v Parliament and Council Case C-377/98 Decision of 9 Oct 2001.

Novartis/Transgenic Plant [1999] EPOR 123.

Novartis AG [1999] EPO 20 Dec 1999.

NRDC's Application [1961], RPC 135.

Parker, Acting Comr. Patents v Flook 198 USPQ 195 [1978].

Plant Bioscience Ltd Case G2/07, European Patent 1069819.

Plant Genetic Systems NV et al. [1995] EPOR 357.

PLG Research Ltd and another v Ardon International Ltd and others [1993] FSR 197.

Public Varieties of Mississippi Inc v Sun Valley Seed Co. Inc. 14 USPQ 2d 2055.

Regents of the University of California v Eli Lilly and Co. 43 USPQ 2 d 1389[1997].

Richard v Du Bon 103 F 868 2nd Circuit [1900].

In the Matter of an Application for a Patent by Rufus Riddlesbarger 53 RPC 57 [1935]

Ex parte Schreiner 1970 vol. 1 International Review of Industrial Property and Copyright Law 136.

SmithKline Beecham PLC's (Paroxetine Methanesulfonate) Patent [2006] RPC 10

State of Israel - Ministry of Agriculture Case G 1/08, European Patent 1211926.

Swift & Co.'s Application [1961] RPC 129.

Synergistic Herbicides case no. T 68/85, OJ 6/1987.

Ex parte Tanksley 26 USPQ 1348 [1991].

Technograph Printed Circuits Ltd v Mills and Rockley (Electronics) Ltd [1972] RPC 346.

University of Utah Research Foundation Case T 1213/05, Technical Board of Appeal EPO, 27 September 2007.

University of Utah Research Foundation Case T 0666/05, Technical Board of Appeal EPO, 13 November 2008.

University of Utah Research Foundation Case T 0080/05, Technical Board of Appeal EPO, 19 November 2008.

Upjohn's Application no. 89913146.0.

Valensi v British Radio Corp [1973] RPC 337.

Windsurfing International Ltd v Tauber Marine (GB) Ltd [1985] RPC 59.

Yoder Bros. Inc. v California-Florida Plant Corp. 537 F 2d 1347 [1976]

#### Table of Statutes

```
1624 Statute of Monopolies:
        s.6
1790 and 1793 Patent Act (USA):
        Article 1, s.8, clause 8
1883, 1907 and 1919 Patent and Designs Act:
         s.86
        s.97
1930 Plant Patent Act (USA):
        Chapter 15
1949 Patents Act:
         s.10(1)(b)
         s.32(1)(e)
         s.32(1)(f)
         s.50(1)
         s.101
         s.102(1)
         s.102(2)
1952 Patent Act (Title 35 United States Code):
         s.101
         s.102
         s.103
         s.112
         s.161
         s.162
         s.163
         s.164
1956 Copyright Act:
         s.10
1970 Plant Variety Protection Act (USA):
         s.2542
         s.2543
         s.2544
         s.2545
1977 Patents Act:
         s.1(1)
         s.1(2)
         s.3
```

```
s.4(1)
s.14(3)
s.14(5)(c)
s.60(5)(a)
s.60(5)(b)
s.72(1)(c)
s.125(1)
s.130(7)
```

1980 Plant Varieties (Proprietary Rights) Act

1980 Patent and Trademark Amendment Act (USA)

1986 Technology Transfer Act (USA)

2000 Patents Regulations

2000 European Communities (Legal Protection of Biotechnological Inventions)

Regulations, S.I. no 247 of 2000, Ireland

## **Table of Conventions**

1883 Paris Convention for the Protection of Industrial Property:	
Art. 1	
Art. 2	
Art. 4	
Art. 19	
1950 European Convention on Human Rights and Fundamental Freedoms: Art. 3	
1953 European Convention Relating to the Formalities Required for Patent	
•	
Applications	
1954 The Council of Europe Convention on the International Classification of	
Patents for Inventions 1961 The International Convention for the Protection of New Varieties of Plants:	
Art. 1	
Art. 2(1)	
Art. 3	
Art. 4	
Art. 5	
Art. 6	
Art. 7	
Art. 8	
Art. 9	
1963 The Convention on the Unification of Certain Points of Substantive Law on	
Patents for Inventions (Council of Europe, European Treaty Series No. 47):	
Art. 2(a)	
Art. 2(b)	
Art. 4(2)	
Art. 5	
Art. 8(3)	
1970 Patent Cooperation Treaty:	
Ch. 2	
Art. 33	
1973 Convention on the Grant of European Patents:	
Art. 52(2)	
Art. 53(a)	
Art. 53(b)	
Art. 63	
Art. 67	

```
Art. 83
        Art. 84
        Art. 138(1)
1975 Community Patent Convention
1990 Deliberate Release Directive
1991 The International Convention for the Protection of New Varieties of Plants:
        Art. 1(vi)
        Art. 3
        Art. 7
        Art. 8
        Art. 9
        Art. 13
        Art. 14(1)(a)
        Art. 14(2)
        Art. 14(3)
        Art. 14(5)(b)
        Art. 14(5)(c)
        Art. 15(1)
        Art. 15(2)
         Art. 16
        Art. 17(1)
         Art. 17(2)
1992 United Nations Convention on Biological Diversity, 31 International Legal
   Materials (1992) 818:
         Art. 2
1994 Agreement on Trade-Related Aspects of Intellectual Property Rights, 33
   International Legal Materials (1994) 81:
         Art. 27(2)
         Art. 29(1)
         Art. 30
         Art. 33
1994 Community Plant Variety Rights, Council Regulation (EC) no 2100/94, O J
   EC L 227/1
         Art. 1
         Art. 3
         Art. 13(1)
         Art. 13(2)
         Art. 13(3)
         Art. 13(4)
         Art. 13(5)
         Art. 13(8)
         Art. 14(1)
         Art. 14(3)
         Art. 15
```

```
Art. 16
        Art. 29
        Art. 92(1)
1995 Commission Regulation (EC) No. 1239/95 31 May 1995, No. L 121/37
1996 Commission Regulation (EC) No. 448/96 12 Mar 1996, No. L 62/3
1997 Convention on Human Rights and Biomedicine, Council of Europe European
   Treaty Series No. 164
1998 Directive on the Legal Protection of Biotechnological Inventions:
Recital 10
Recital 16
Recital 38
        Recital 43
        Art. 2(1)(a)
        Art. 4
        Art. 4(1)
        Art. 4(2)
        Art. 5(1)
        Art. 5(2)
        Art. 5(3)
        Art. 6(1)
        Art. 6(2)
        Art. 6(2)(d)
        Art. 8(1)
        Art. 8(2)
        Art. 11(1)
        Art. 11(2)
        Art. 11(3)
        Art. 12(1)
        Art. 12(2)
        Art. 12(3)
        Art. 12(4)
2000 European Patent Convention (Amended)
        Art. 53(c)
2001 Deliberate Release Directive, Dir. 2001/18/EC
2007 Patent Reform Act 2007, USA
```

#### Preface to the Revised Edition

The biotechnology industry is at the cutting edge of scientific research and innovation. The result is that communities, human and non-human, stand on the threshold of an extraordinary revolution that will have profound effects on their relationship with other creatures and the environment. This has resulted in much political debate because countries have fundamentally differing views about biotechnology. In addition, there are divergent views concerning the legal, moral, ethical and social problems connected with the technology. In order to orchestrate an informed debate among the public about the practice and application of biotechnology, scientists and non-scientists alike must work together in an effort to understand what biotechnology can and cannot do. While scientists are capable of identifying the potential advances in the fields of healthcare, agriculture and the food industry that might flow from the commercial application of the technology, only the public can decide their degree of importance and assess the benefits, hazards and impact. Such fundamental decisions can be made only within a properly constituted framework. Law can provide the mechanisms that facilitate the taking of necessary decisions about the nature and direction of both research and policy. In this regard, there are moral objections both to the technology itself and the patenting of biotechnological inventions. The patenting process stands at the confluence of science and technology, on the one hand, and law on the other. In several respects, the intertwining of two disciplines creates tensions not only at the national, but also the international, level. Problems arise because there are differences in matters such as: concepts justifying patent protection; patent law as a matter of economic policy; and patent law as an integral part of the general legal system of the country concerned.

Biotechnology has always been part of our heritage. However, it has been of special concern only since the novel use of organisms in the context of DNA structure was discovered. While developed initially in the area of lower organisms, modern genetic technologies are increasingly applied to more complex biological entities, giving rise to previously unknown, or little-known, concerns of a moral nature.

The advent of biotechnology has posed significant challenges for patent law. As in any legal system there are areas of contention and uncertainty as to the application of legal provisions to particular fact situations. The nature of the subject-matter gives rise to complex conceptual, theoretical and moral questions, particularly in regard to the application of exclusions to patentability of biotechnological inventions.

In its first edition, published in 2005, this book outlined the moral debate surrounding biotechnology and the patenting of biotechnological inventions. The aims of the European Patent Convention were examined and showed that a 'light' moral regime was intended. This compared favourably with the approach to the question of morality in the United States. The book also examined European Patent Office jurisprudence in the light of the policies underlying the exceptions to patentability; in regard to UK Patent Office jurisprudence the cases demonstrated that sufficient difficulties arise when traditional substantive patent law criteria are applied to new technologies without additional assessment of moral concerns. This was compared with protection available to innovators in the biological field in the United States. The Biotechnology Directive 1998 was outlined and assessed in order to determine the extent to which it allows the European Patent Office and national patent-granting authorities to interpret in the same way those provisions of patent law that apply to biotechnological inventions. In addition, the book examined why plant variety rights systems form a part of the critique of the Directive. In European states, developments showed an attempt by the European Union and European Patent Office to confine morality to commercial situations and to bring the European Patent Convention within the confines of the EU.

In such a fast-moving field as biotechnology there has been a plethora of new published material. Much of this emphasizes the higher public profile of debates associated with the technology and includes ethical and privacy issues surrounding the development of bio-banking, including cord blood banking and DNA profiling, and issues surrounding new therapeutic applications in regenerative medicines. Such subjects are undoubtedly interesting but are clearly outside the scope of this work, which is concerned with the legal framework associated with biotechnological inventions.

While there have been no radical changes to the law since publication of the first edition in 2005, there has been a steady accretion of the law. In this regard, the revised edition outlines developments and continues with a focused discussion of specific legal provisions. In particular, the Revised European Patent Convention 2000 (in force 2007) is important. It now incorporates the Biotechnology Directive 1998, and in this regard, Rule 28 EPC 2000 and Rule 29 EPC 2000 are examined to determine the extent to which harmonization of law has been facilitated. Public policy, and changes relating to Article 52(4) EPC 1973, now appearing as the new Article 53(c) EPC 2000, are examined. The revised edition reviews case law developments and examines, in particular, the application of Article 53(a) in relation to stem cells and human genetics. Additionally, new cases have been included to assess whether or not consistency of practice has been achieved by the courts in respect of more traditional patentability criteria. Monitored also through case law developments is how patent law reform in Europe, through the European Patent Office, is expanding; in contrast, patent law reform in the United States, through the Patent and Trademark Office, may now be curtailed. Also discussed are the most recent European Commission communications which highlight the importance of the link between patents and innovation. The European Commission Proposal for a Regulation is aimed at creating a new unitary industrial property right, the Community patent. This, the Commission believes, is essential for eliminating the distortion of competition resulting from the territorial nature of national protection rights.

## Acknowledgements

I wish to thank Ashgate Publishing Ltd for agreeing to publish the revised edition of this book. In particular, Mr John Irwin, Consultant Publisher, and Ms Alison Kirk, the Law Publisher, without whose help this work would not have been completed.

Readers are advised that any shortcomings in the revised edition are solely my responsibility and that no liability will be accepted in respect of any reliance thereon.

#### List of Abbreviations

AIPPI International Association for the Protection of Industrial Property

ASSINEL International Association of Plant Breeders for the Protection

of Plant Varieties

BIRPI Bureaux internationaux réunis pour la protection de la

propriété intellectuelle

CAFC Court of Appeals for the Federal Circuit
CCPA Court of Customs and Patent Appeals
CPVR Community Plant Variety Rights 1994
ECHR European Convention on Human Rights

ECJ European Court of Justice

EEC European Economic Community

EFTA European Free Trade Area

EGE European Group on Ethics in Science and New Technologies

EPC European Patent Convention
EPO European Patent Office

EPOR European Patent Office Reports

EU European Union FSR Fleet Street Reports

GAEIB Group of Advisors on Ethical Implications of Biotechnology

OJ Official Journal of the European Communities

PCT Patent Cooperation Treaty 1970

PIP 1883 Paris Convention for the Protection of Industrial Property

PPA 1930 Plant Patent Act

PTO US Patent and Trademark Office PVPA 1970 Plant Variety Protection Act

RPC Reports on Patent Cases

TRIPS 1994 Agreement on Trade-Related Aspects of Intellectual

**Property Rights** 

UPOV 1961 International Union for the Protection of New Varieties of

Plants 1961 Act

UPOV 1991 International Union for the Protection of New Varieties of

Plants 1991 Act

USC United States Code

USPO United States Patent Quarterly

WIPO World Intellectual Property Organization

## Contents

Table of Cases Table of Statutes		vii xi
Preface to the Revised Edition		xvii
	Acknowledgements  List of Abbreviations  Biotechnological Inventions: The Moral Debate	
1	Biotechnological Inventions: The Moral Debate	1
2	Development of a European and UK Moral Regime	19
3	Development of Patent Law in the United States	41
4	Application of Article 53 European Patent Convention	53
5	Patent Law Criteria and Biotechnological Inventions	81
6	Protection Conferred in the United States	115
7	Protection Conferred under the Biotechnology Directive 1998	131
8	Plant Variety Protection: UPOV, Community, Directive	155
9	Recent EU Initiatives: Likely Impact on Moral Concerns	185
Rib	liography	197
	index	
_,,_,,	<del></del>	213